UBS Group
VKTX icon

UBS Group’s Viking Therapeutics VKTX Stock Holding History

UBS Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,800
Closed -$1.4M – 11212
2025
Q4 		$1.4M Sell
39,800
-30,200
-43% -$1.07M ﹤0.01% 5286
2025
Q3 		$1.84M Buy
+70,000
New +$2.09M ﹤0.01% 5034
2024
Q3 		– Sell
-26,500
Closed -$1.4M – 10104
2024
Q2 		$1.4M Buy
+26,500
New +$1.74M ﹤0.01% 4107

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

UBS Group's VKTX Position: Q1 2026 in Review

UBS Group increased its Viking Therapeutics (VKTX) stake by 44% in Q1 2026, buying an estimated $13.3M and bringing the position to 1,347,472 shares worth $43.8M. The position accounts for 0.01% of the portfolio, ranked #1782.

UBS Group first reported a position in VKTX in Q3 2015 and has held it in 38 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • UBS Group held 1,347,472 shares of Viking Therapeutics worth $43.8M as of Q1 2026.
  • UBS Group bought 412,547 Viking Therapeutics shares in Q1 2026, an estimated $13.3M.
  • Viking Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1782 holding.
  • UBS Group first reported a position in Viking Therapeutics in Q3 2015 and has held it in 38 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.